Low-density neutrophil heterogeneity and spleen tyrosine kinase as therapeutic targets in sepsis
Authors:
- Heather L. TeagueHTHeather L. Teague
- Lauren KnabeLKLauren Knabe
- Xianglan YaoXYXianglan Yao
- Kiana C. AllenKAKiana C. Allen
- Trenton WilliamsTWTrenton Williams
- Cumhur Y. DemirkaleCDCumhur Y. Demirkale
- Merte WoldehannaMWMerte Woldehanna
- Ernest EvansEEErnest Evans
- Amir HobsonAHAmir Hobson
- Jared D. WilkinsonJWJared D. Wilkinson
- Steven D. NathanSNSteven D. Nathan
Open Access
- 21 April 2026
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (11)
Abstract
Sepsis is a leading cause of death for which host-directed therapies are urgently needed. We performed high-dimensional flow cytometry, measurement of soluble biomarkers, and lipopolysaccharide (LPS) stimulation of neutrophils to characterize neutrophil heterogeneity and function in patients with sepsis. We observed that in patients with sepsis, low-density neutrophils (LDNs) are elevated and phenotypically diverse populations of innate immune cells with varying degrees of maturity and myeloperoxidase expression. Spleen tyrosine kinase (SYK) expression was found to be higher in whole blood neutrophils and LDNs of patients with sepsis compared with healthy donors. Importantly, SYK + LDNs associated with increased levels of intracellular myeloperoxidase (MPO) and soluble biomarkers. Furthermore, SYK + LDNs correlated with clinical outcomes of sepsis disease severity, including sequential organ failure assessment score, mechanical ventilation, and vasopressors. Functionally, the SYK inhibitor R406 suppressed changes in neutrophil features of activation from normal-density neutrophils and LDNs, including the SYK + and SYK – neutrophil subsets, and MPO release from LDNs following LPS stimulation of sepsis neutrophils. Combined, these results establish LDNs as a heterogenous population of neutrophils that express high levels of SYK and support SYK inhibition as a potentially novel therapeutic target aimed at suppressing overactive neutrophils in sepsis.Keywords
Funding Information
- Division of Intramural Research (N/A)
This publication has 44 references indexed in Scilit:
- Fostamatinib for Hospitalized Adults With COVID-19 and HypoxemiaJAMA Network Open, 2024
- Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021Intensive Care Medicine, 2021
- Emergence of immunosuppressive LOX-1+ PMN-MDSC in septic shock and severe COVID-19 patients with acute respiratory distress syndromeJournal of Leukocyte Biology, 2021
- Low‐Density Neutrophils in Systemic Lupus ErythematosusArthritis & Rheumatology, 2020
- On the origin of low-density neutrophilsJournal of Leukocyte Biology, 2020
- Amelioration of sepsis-induced acute kidney injury through inhibition of inflammatory cytokines and oxidative stress in dendritic cells and neutrophils respectively in mice: Role of spleen tyrosine kinase signalingBiochimie, 2019
- Improving Long-Term Outcomes After SepsisCritical Care Clinics, 2018
- Incidence and Trends of Sepsis in US Hospitals Using Clinical vs Claims Data, 2009-2014JAMA, 2017
- The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)JAMA, 2016
- Value of plasma neutrophil gelatinase-associated lipocalin in predicting the mortality of patients with sepsis at the emergency departmentClinica Chimica Acta, 2016